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A novel immunotherapy platform is represented by the
DCOne cell line, which originates from a human myeloid
leukemia cell line, endogenously expresses a range of leu-
kemia associated antigens, including PRAME and WT-1,
and can be differentiated into mature dendritic cells (DC).
This cell line is being developed to replace patient-derived
DC vaccines. The first indication in which mature DC
derived from DCOne have been tested clinically is Acute
Myeloid Leukemia (AML). A Phase I/IIa study enrolled 12
AML patients (age range 58-71) who were either in CR1/
CR2 (n=5) or had smouldering disease (n=7). Patients
had received all available standard care, were at high
risk of relapse and ineligible for available post-remission
therapies. A typical 3+3 design was used, starting with
4 bi-weekly intradermal DCOne DC vaccinations of 10E6
(n=3), 25E6 (n=3) or 50E6 cells(n=6). Patients were moni-
tored for clinical and immunological responses for
126 days. Primary endpoints were safety and feasibility,
and secondary endpoints were clinical and immunological
responses. Treatment was well tolerated in all patients,
with only injection site reactions (< grade 2). During
the study 3 patients died: 2 from infections and 1 from
leukemia. Clear evidence for induction of multi-functional
immune responses was obtained, including increased post
vaccination delayed type hypersensitivity reactions,
increases in CD4+ and CD8+ T cell proliferative responses
and/or seroconversion to DCOne DC and/or AML blasts
in 6 out of 9 patients. Also, 3 out of 7 patients that were
evaluable by IFNg ELIPOTs showed vaccination-induced
specific T cell responses to WT-1 and/or PRAME. Patients
who survived more than 6 months post-vaccination
showed remarkable survival (4 patients are still alive 27,
21, 12 and 9 months after study entry). One of these
patients, with smouldering AML at entry, achieved CR2
after vaccination; one patient who was in CR2 at entry
relapsed 8 months after vaccination, entered CR3 follow-
ing a single low dose of 5-AZA and survived until
23 months. The two most recently enrolled patients
recruited are still in remission at 12 and 9 months.
We conclude that vaccination with DCOne derived DC is
feasible in AML, and generates both cellular and humoral
immune responses. The hypothesis that DCOne-derive
DC induce immune responses against patient leukemia
cells correlate with clinical benefit, will now be investi-
gated in a multi-center randomized Phase II trial in AML
patients in first remission.
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